Drug Approval | March 22, 2022
Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
The medicine is now approved for eight indications across five different types of cancer in China.
Diversifying its portfolio to include late-phase antiviral agent
OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy
Subscribe To Our Newsletter & Stay Updated
